DiscoverX/PathHunter Panitumumab Bioassay Kit/93-1051Y3-00094/1000dp(10x96-well)
DiscoverX® is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other turnkey solutions for the drug discovery, screening, and life science mark...
ThePathHunter®DimerizationBioassaydetectsligandinduceddimerizationoftwosubunitsofareceptor-dimerpair.Thecellshavebeenengineeredtoco-expressonereceptorsubunitfusedtoEnzymeDonor(ED),andaseconddimerpartnerfusedtoEnzymeAcceptor(EA).Cytoplasmictailmayhavebeendeletedfromoneorbothreceptors.BindingofanagoNISTtoonereceptorsubunitinducesittointeractwithitsdimerpartner,forcingcomplementationofthetwoenzymefragments.Thisresultsintheformationofafunctionalenzymethathydrolyzesasubstratetogenerateachemiluminescentsignal.Target/DescriptionEpidermalgrowthfactorreceptorGroupReceptorTyrosineKinaseCellBackgroundU2OSSpeciesHumanAccessionNumberNM_005228.3Agonist/LigandEGFAntagonist/InhibitorVectibix(Panitumumab)AssayMeasuresEGFR/ErbB2DimerizationBioassayTargetNameEGFR/ErbB2AssayQualifiedWithVectibix®DrugTrademarkOwnerVectibix®isaregisteredtrademarkofAmgenInc.Howitworks
DiscoverX is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other turnkey solutions for the drug discovery, screening, and life science markets. Our biochemical and cell-based assays enable customers to improve research productivity and effectiveness of their screening, lead optimization and SAR campaigns, thus accelerating the discovery and development of new drugs. Plus, with the addition of the BioMAP platform of human primary cell systems for phenotypic profiling, DiscoverX offers a powerful tool to deliver physiologically relevant insights and integrated solutions for all stages of discovery from target and lead discovery to preclinical and beyond.
Business Overview Founded in 2000, DiscoverX is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, South San Francisco and Birmingham, England. DiscoverX is dedicated to the development and commercialization of innovative solutions for discovery research.
Proven Technology The Company pioneered the use of β-galactosidase enzyme fragment complementation (EFC) for discovery research. EFC technology is a proven, established screening platform in most major pharmaceutical companies and our EFC-based HitHunter cAMP assays are the market leader in GPCR screening applications. PathHunter and InCELL Hunter™ technology platforms, an adaptation of EFC technology, are an innovative and comprehensive assay system that enables live cell-based assays for pathway profiling and compound screening.
In addition to the EFC platform, DiscoverX also holds extensive intellectual property for its second core technology, an in vitro binding assay platform called KINOMEscanSM. Through our core technologies, DiscoverX is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, bromodomains, methyltranseferases, proteases, nuclear hormone receptors, cytokines, transcription factors and secreted proteins.
Corporate Partnerships DiscoverX remains committed to fully exploit the commercial potential of its EFC as well as KINOMEscan technology either solely or with its corporate partners. DiscoverX values such partnerships and is actively seeking additional collaborative alliances to commercialize and provide early access to new technology platforms in the drug discovery and development markets.
苏州蚂蚁淘生物科技有限公司是一家创新型高科技生物公司，以常规生物学实验外包与生物学试剂为基础，放眼于生命科学领域的前沿技术服务，公司技术骨干有着多年的生物学科研背景，毕业于国内外名牌大学，并且有着丰富的项目经验，了解国内外科研行情，我公司力求为每一个客户提专业、针对性的实验方案。我公司以技术服务为支点，和国内外多家生物试剂公司有着密切的业务往来.公司特色技术服务包括：抗体药物研发、噬菌体抗体库、蛋白表达与传化、抗体制备、高通量测序、组学研究、生物信息学分析与方法建立、基础分子生物学技术外包、化学中间体合成、原料药物研发、论文编写等。我公司秉承”诚信做人，认真做事，服务至上“，希望用我们的专业知识和项目经验为国内科研客户解决科研问题，祝您科研之路畅通无阻！
Eurofins DiscoverX公司成立于2000年，2017年被Eurofins Pharma Discovery Services收购。是一家研发生产销售商业化试剂的创新性公司。主营业务是细胞的检测试剂盒，分析和筛选服务以及用于提供药物发现，筛选和生命科学市场的其他重要解决方案。我们的生物化学和基于细胞的分析能够帮助客户提高科研效率，从而加速新药物的发现和开发。 该公司率先使用β-半乳糖苷酶片段互补（EFC）进行发现研究。EFC技术是大多数主要制药公司经过验证的，建立的筛选平台，我们基于EFC的HitHunter cAMP分析是GPCR筛查应用领域的市场。PathHunter 和InCELL Hunter™技术平台是EFC技术的一种改进，它是一种创新且全面的测定系统，可用于通路分析和化合物筛选的基于活细胞的分析。 除了EFC平台之外，Eurofins DiscoverX还拥有其第二项核心技术-一种名为KINOMEscanSM的体外结合测定平台。通过我们的核心技术，Eurofins DiscoverX能够为每一类主要药物靶点提供检测解决方案，包括GPCRs，激酶，溴结构域，甲基转移酶，蛋白酶，核激素受体，细胞因子，转录因子和分泌蛋白。 DiscoverX全国代理，部分产品列表：
